Abstract:Objective To assess the efficacy and safety of leflunomide in active ankylosing spondylitis.Methods Totally 62 cases of active ankylosing spondylitis were included,and divided randomly into leflunomide group(n=26)and methotrexate group(n=36).The patients in leflunomide group received an oral leflunomide loading dose of 50 mg or 40 mg once daily for the first 3 days followed by a maintenance dose of 50 mg or 40 mg once weekly,according to whether the bodyweight was more than 50 kg or less than 50 kg,respectively.The patients in methotrexate group were prescribed oral methotrexate 5 mg once in the first week,10 mg once in the second week,15 mg once in the third week and thereafter weekly.Sulfasalazine was prescribed 0.75 three times daily in both groups.The Bath Ankylosing Spondylitis Disease Activity Index(BASDAI)and The Bath Ankylosing Spondylitis Metrology Index(BASIM)scoring instruments were used to assess the responsiveness to leflunomide and methotrexate at entry,three months,six months,twelve months and eighteen months after treatment,respectively.Laboratory data including peripheral blood counts(WBC,HGB,RBC),erythrocyte sedimentation rates(ESR),liver enzymes,serum creatinine,urinary sediments were detected at the same time.Sacroiliac joints CT scan and other involved joints x-ray radiograph examinations were taken at entry,six months,twelve months and eighteen months after treatment,respectively.Results Twenty-two cases in leflunomide group and 29 cases in methotrexate group were followed up to eighteen months.BASDAI in leflunomide group was significantly lower(P0.01)compared with MTX group from six months.As to BASMI and ESR,there were no differences between the two groups at three months,six months,twelve months and eighteen months.No deterioration with sacroiliac joints on CT scan and the involved joints on x-ray radiographs in the two groups was found.The incidence rate of adverse events were higher in MTX group than LEF group.Conclusion Leflunomide shows the same efficacy as methotrexate in active ankylosing spondylitis,while the adverse effects are mild compared with methotrexate.

Methotrexate versus sulfasalazine in the treatment of ankylosing spondylitis

Long-term efficacy of sulfasalazine,methotrexate and sulfasalazine combined with methotrexate in treatment of ankylosing spondylitis:a clinical study

Methotrexate for hip involvement of ankylosing spondylitis:a clinical study

Meta-analysis of the effectiveness and safety of sulfasalazine in the treatment of ankylosing spondylitis

Efficacy of Yishen Juanbi Oill on Ankylosing Spondylitis

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

Treatment of Active Ankylosing Spondylitis with Leflunomide and Methotrexate : a Prospective Controlled Clinical Trial

Clinical study on long-term effectiveness of leflunomide compared with sulfasalazine in treatment of ankylosing spondylitis

Efficacy of Biological Agents Combined with Methotrexate and Sulfasalazine for Ankylosing Spondylitis with Hip Joint Involvement

Clinical Observation on Total Glucosides of Paeony Combined with Sulfasalazine in Treatment of Ankylosing Spondylitis

Short Research on the Efficacy and Safety of Methotrexate Combined with the TNF-α Receptor Fusion Protein Etanercept in Patients with Severe Undifferentiated Spondyloarthropathy

[Radiological Progression and Life Quality Analysis in Ankylosing Spondylitis Patients Using Etanercept/methotrexate Combination Therapy].

Safety and Efficacy of Etanercept-Methotrexate Combination Therapy in Patients with Rhupus: an Observational Study of Non-glucocorticoid Treatment for Rheumatic Diseases

Methotrexate Combined with Conventional DMARDs or Biological Agents for Rheumatoid Arthritis

Methotrexate for chronic non-necrotizing anterior scleritis in Chinese patients

Efficacy and Safety of Intra-Articular Therapy with Methotrexate in Large Volume of Glucose Injection on Knee Synovitis in Patients with Ankylosing Spondylitis

Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis

Clinical trial of Leflunomide in active ankylosing spondylitis

Combined Bushen Qiangdu Recipe and sulfasalazine treatment reduced cytokine levels and improved the symptoms of ankylosing spondylitis

Effectiveness and Safety of Methotrexate Versus Leflunomide in 12-Month Treatment for Takayasu Arteritis.

Clinical Observation on Recombinant Human TypeⅡTumor Necrosis Factor Receptor-antibody Fusion Protein and Immunosuppressive Agents in Treatment of Patients with Ankylosing Spondylitis